Gritstone bio, Inc.
Gritstone bio, Inc. (GRTS): 3 pipeline candidates · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.9 months
D/E 5.42 · 22% dilution
Lead: Phase 2/Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for Gritstone bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$56.9M
Quarterly Burn
$26.8M
Runway
6.9 mo
Revenue
$921K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Gritstone bio, Inc.'s pipeline?
Gritstone bio, Inc. (GRTS) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Gritstone bio, Inc.'s lead drug candidate?
Gritstone bio, Inc.'s most advanced tracked candidate is coral (Phase 2) for COVID-19.
What is Gritstone bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Gritstone bio, Inc. has approximately 6.9 months of cash runway.
Who is the CEO of Gritstone bio, Inc.?
Andrew Allen, M.D. is the chief executive officer of Gritstone bio, Inc. (GRTS).
Get the full picture on Gritstone bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.